Skip to main content

Day: May 26, 2020

ALBIOMA : Assemblée Générale Mixte du 29 mai 2020 – Modalités de rediffusion de la séance

Communiqué de presseParis La Défense, le 26 mai 2020Assemblée Générale Mixtedu 29 mai 2020Modalités de retransmission de la séanceCompte tenu du contexte sanitaire lié à l’épidémie de Covid-19, Albioma rappelle à ses actionnaires que l’Assemblée Générale annuelle se tiendra à huis clos le 29 mai 2020 à 15 heures, conformément à l’ordonnance n° 2020-321 du 25 mars 2020.La séance de l’Assemblée Générale sera retransmise en direct. Pour accéder à l’évènement, les actionnaires sont invités à se connecter :soit par Internet, en cliquant sur le lien ci-dessous ou en le recopiant dans la barre d’adresse d’un navigateur : https://globalmeet.webcasts.com/starthere.jsp?ei=1321005&tp_key=9329b6201dsoit par téléphone, en composant le +33 1 70 61 85 22 depuis la France, puis le code 39625831#.Seul l’accès Internet permettra le visionnage de la...

Continue reading

Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitisIn the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS aloneThree-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%Safety consistent with the established safety profile of Dupixent across adult and adolescent atopic dermatitis patientsPARIS and TARRYTOWN, N.Y. – May 26, 2020 – The U.S. Food and Drug Administration (FDA)  approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately...

Continue reading

Sanofi: La FDA approuve Dupixent® (dupilumab), premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 à 11 ans  

La FDA approuve Dupixent® (dupilumab), premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 à 11 ans  Dans le cadre d’un essai pivot, plus du double d’enfants traités par Dupixent et des corticoïdes topiques ont obtenu une cicatrisation complète ou quasi-complète de leur peau et plus de quatre fois plus d’entre eux une réduction des démangeaisons, comparativement à ceux traités par corticoïdes topiques seulementTrois-quarts des patients traités par Dupixent ont obtenu une amélioration d’au moins 75 % des symptômes globaux de la maladie, avec une amélioration moyenne d’environ 80 %   Profil de tolérance cohérent avec le profil établi de Dupixent chez les patients adultes et adolescents atteints de dermatite atopiquePARIS et TARRYTOWN (New York) – Le 26 mai 2020 – La Food...

Continue reading

Treasury Bill Auction Announcement – RIKV 20 1005 – RIKV 20 1215

On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bills in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury Bills must be received by the Central Bank before 14:00 on the Settlement Date, and the Bills will be delivered in electronic form on the same day.Further reference is made to the General Terms of Icelandic Treasury bills and General Terms of Auction for Treasury bills on the Government Debt Management website.For further information please contact Laufey B. Ómarsdóttir, Government Debt Management, at +354 569 9631.

Continue reading

Tilkynning um útboð ríkisvíxla – RIKV 20 1005 – RIKV 20 1215

Á útboðsdegi, á milli kl. 10:30 og 11:00, fer fram útboð hjá Lánamálum ríkisins á ríkisvíxlum í þeim flokkum, með þeim ISIN númerum og með þeim gjalddögum sem fram koma í töflunni hér að ofan. Greiðsla fyrir ríkisvíxlana þarf að berast Seðlabankanum fyrir kl. 14:00 á uppgjörsdegi og verða bréfin afhent rafrænt sama dag.Að öðru leyti er vísað til almennrar lýsingar íslenskra ríkisvíxla og almennra útboðsskilmála á heimasíðu Lánamála ríkisins.Nánari upplýsingar veitir Laufey B. Ómarsdóttir, Lánamálum ríkisins í síma 569 9631.

Continue reading

CORRECTION ET MISE À JOUR – Les réseaux mobiles dans les régions rurales au Canada sont parmi les plus rapides au monde

Le communiqué suivant corrige et remplace le communiqué de presse intitulé “Le Canada arrive au deuxième rang des pays du G7 pour les vitesses de téléchargement mobiles dans les régions rurales” diffusé le 26 mai 2020 à 9:00 AM HAE par TELUS Communications Inc. La version complète et corrigée suit : Les réseaux mobiles dans les régions rurales au Canada sont parmi les plus rapides au mondeTELUS offre le réseau le plus rapide dans les régions rurales du paysLes vitesses de téléchargement dans les zones rurales au Canada se classent deuxième parmi les pays du G7Les investissements technologiques soutenus de TELUS dans son réseau en régions rurales ont permis une augmentation de 71 % des vitesses de téléchargement sur un anTORONTO, 26 mai 2020 (GLOBE NEWSWIRE) — Les vitesses de téléchargement en régions rurales du Canada...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.